公开(公告)号：EP4098653A1

公开(公告)日：2022-12-07

申请号：EP20916984.6

申请日：2020-03-26

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences ,  Frontier Biotechnologies Inc.

发明人： LIU, Hong ,  LI, Jian ,  DAI, Wenhao ,  PENG, Jingjing ,  XIE, Xiong ,  HU, Shulei ,  LI, Chunpu ,  XU, Yechun ,  YANG, Haitao ,  ZHANG, Leike ,  SU, Haixia ,  JIANG, Hualiang ,  JIN, Zhenming ,  XIAO, Gengfu ,  CHEN, Kaixian

IPC分类号： C07D405/12 ,  A61K31/437

摘要： Use of an aldehyde-based compound as represented by general formula I, a pharmaceutical composition, a pharmaceutical salt, an enantiomer, a diastereomer and a racemic compound thereof as a novel coronavims 2019 (2019-nCov) 3CL protease inhibitor in preparation of a medicament for treating and/or preventing and relieving respiratory tract infections, pneumonia and other related diseases caused by the novel coronavims infection 2019.

公开(公告)号：EP4098258A1

公开(公告)日：2022-12-07

申请号：EP21748369.2

申请日：2021-01-28

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： LIU, Hong ,  LI, Jian ,  PENG, Jingjing ,  XIE, Xiong ,  DAI, Wenhao ,  HU, Shulei ,  LI, Chunpu ,  ZHANG, Leike ,  JIN, Zhenming ,  XU, Yechun ,  XIAO, Gengfu ,  YANG, Haitao ,  BAI, Fang ,  CHENG, Xi ,  JIANG, Hualiang ,  CHEN, Kaixian

IPC分类号： A61K31/404 ,  A61K31/4412 ,  A61K31/4025 ,  A61K31/4439 ,  A61K31/498 ,  A61K31/4709 ,  A61K31/443 ,  A61K31/4155 ,  A61K31/437 ,  A61P11/00 ,  A61P31/14

摘要： Use of a class of ketoamide-based compounds, in particular, use of the ketoarnide-based compound as represented by general formula A as a 2019 novel coronavirus (2019-nCov) 3 CL protease inhibitor and/or human cathepsin L inhibitor in preparation of a medicament for treating and/or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019 novel coronavirus infection. The present invention also relates to use of pharmaceutical compositions of the class of compounds, pharmaceutical salts, enantiomeric forms, diastereoisomers and racemic compounds thereof in preparation of a medicament for treating and/or preventing and relieving respiratory tract infections and other related diseases caused by the 2019 novel coronavirus infection.